XENE Stock Price, Xenon Pharmaceuticals Quote, Chart

Market Summary

USD40.50-0.04

Market Closed

-0.10%

XENE Stock Price

View Fullscreen

XENE RSI Chart

XENE Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-16.21

Price/Sales (Trailing)

340.07

EV/EBITDA

-16.2

Price/Free Cashflow

-19.38

XENE Price/Sales (Trailing)

XENE Profitability

EBT Margin

-2000.92%

Return on Equity

-21.25%

Return on Assets

-20.52%

Free Cashflow Yield

-5.16%

XENE Fundamentals

XENE Revenue

Revenue (TTM)

9.4M

XENE Earnings

Earnings (TTM)

-188.6M

Earnings Growth (Yr)

-14.87%

Earnings Growth (Qtr)

-7.13%

Breaking Down XENE Revenue

Last 7 days

-6.2%

Last 30 days

-1.9%

Last 90 days

-15.7%

Trailing 12 Months

0.9%

How does XENE drawdown profile look like?

XENE Financial Health

Current Ratio

31.82

Debt/Equity

0.01

Debt/Cashflow

-14.15

XENE Investor Care

Shares Dilution (1Y)

18.73%

Diluted EPS (TTM)

-2.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	22.8M	21.2M	13.2M	9.4M
2021	29.4M	18.3M	19.9M	18.4M
2020	13.9M	27.3M	30.3M	32.2M
2019	0	0	4.2M	7.1M
2017	0	0	1.5M	1.1M
2016	12.2M	8.5M	4.7M	1.8M
2015	27.4M	26.1M	17.2M	15.6M
2014	27.0M	26.7M	29.1M	28.4M
2013	17.6M	20.8M	24.1M	27.4M
2012	0	0	0	14.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Xenon Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 08, 2024	garofalo elizabeth a.	sold	-95,583	45.69	-2,092	-
Mar 08, 2024	garofalo elizabeth a.	acquired	64,960	18.56	3,500	-
Mar 08, 2024	garofalo elizabeth a.	sold (taxes)	-64,993	46.16	-1,408	-
Mar 07, 2024	robin sherrington	sold (taxes)	-69,123	45.96	-1,504	evp, strategy & innovation
Mar 07, 2024	robin sherrington	acquired	85,113	9.85	8,641	evp, strategy & innovation
Mar 07, 2024	gannon steven	sold	-601,615	46.2781	-13,000	-
Mar 07, 2024	robin sherrington	sold	-330,290	46.2786	-7,137	evp, strategy & innovation
Dec 29, 2023	robin sherrington	sold	-	-	-8,398	evp, strategy & innovation
Dec 19, 2023	azab mohammad	acquired	42,552	9.85	4,320	-
Dec 14, 2023	patou gary	sold	-311,898	41.05	-7,598	-

Which funds bought or sold XENE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	CREDIT SUISSE AG/	added	4.33	-93,633	3,673,840	-%
May 10, 2024	CITIGROUP INC	reduced	-19.67	-34,484	103,880	-%
May 10, 2024	WESTFIELD CAPITAL MANAGEMENT CO LP	added	46.26	4,014,440	14,953,500	0.08%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	new	-	788,030	788,030	0.06%
May 10, 2024	JPMORGAN CHASE & CO	reduced	-30.63	-854,880	1,576,540	-%
May 10, 2024	VANGUARD GROUP INC	added	3.75	-451,094	14,449,100	-%
May 10, 2024	BlackRock Inc.	added	2.65	-3,859,920	91,349,000	-%
May 10, 2024	PRINCIPAL SECURITIES, INC.	unchanged	-	-48.00	689	-%
May 10, 2024	Lynwood Capital Management Inc.	sold off	-100	-115,150	-	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	1.87	-887,973	17,659,400	-%

Are Funds Buying or Selling XENE?

Are funds buying XENE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XENE

No. of Funds

Unveiling Xenon Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	driehaus capital management llc	5.88%	4,345,180	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	7.7%	5,666,666	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	wellington management group llp	5.56%	4,162,654	SC 13G
Feb 14, 2023	biotechnology value fund l p	1.1%	681,278	SC 13G/A
Feb 14, 2023	avoro capital advisors llc	7.8%	4,900,000	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	1.9%	1,178,324	SC 13G/A
Feb 10, 2023	driehaus capital management llc	7.49%	4,681,797	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2022	point72 asset management, l.p.	5.8%	2,992,597	SC 13G/A

Recent SEC filings of Xenon Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 19, 2024	8-K	Current Report
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading
Mar 12, 2024	4	Insider Trading

Peers (Alternatives to Xenon Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Xenon Pharmaceuticals Inc News

Latest updates

Xenon Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2017Q4	2017Q3	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4
Revenue	-100.0%	-	132,000	536,000	8,766,000	3,737,000	8,124,000	2,218,000	4,358,000	5,150,000	6,554,000	13,384,000	7,078,000	3,329,000	3,500,000	16,000	264,000	376,000	413,000	413,000	601,000	3,227,000
Operating Expenses	13.3%	43,331,000	38,260,000	30,851,000	26,135,000	28,575,000	23,722,000	24,716,000	20,417,000	18,073,000	16,253,000	14,030,000	15,111,000	14,927,000	12,451,000	-	-	-	-	-	-	-
S&GA Expenses	-3.7%	8,501,000	8,829,000	8,705,000	6,775,000	6,688,000	4,831,000	6,339,000	4,109,000	3,106,000	3,208,000	3,310,000	3,320,000	3,175,000	2,700,000	-	-	-	-	-	-	-
R&D Expenses	18.3%	34,830,000	29,431,000	22,146,000	19,360,000	21,887,000	18,891,000	18,377,000	16,308,000	14,967,000	13,045,000	10,720,000	11,791,000	11,752,000	9,751,000	-	-	-	-	-	-	-
EBITDA Margin	-53.2%	-13.10	-8.56	-4.29	-3.59	-4.23	-3.27	-3.19	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	154,000	330,000	348,000	363,000	-	-	-	-	-	-	-
Income Taxes	294.0%	1,139,000	-587,000	-40,000	-394,000	484,000	-205,000	-217,000	-68,000	-14,000	-203,000	-39,000	-1,000	-36,000	5,000	-	-	-	-	-	-	-
Earnings Before Taxes	3.9%	-36,256,000	-37,737,000	-31,198,000	-20,064,000	-25,080,000	-15,650,000	-22,326,000	-15,832,000	-12,337,000	-9,058,000	-214,000	-7,485,000	-11,412,000	-8,866,000	-	-	-	-	-	-	-
EBT Margin	-53.3%	-13.28	-8.66	-4.35	-3.64	-4.28	-3.33	-3.26	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-0.7%	-37,395,000	-37,150,000	-31,158,000	-19,670,000	-25,564,000	-15,445,000	-22,109,000	-15,764,000	-12,323,000	-8,855,000	-175,000	-7,484,000	-11,376,000	-8,871,000	-	-	-	-	-	-	-
Net Income Margin	-54.2%	-13.29	-8.62	-4.34	-3.62	-4.28	-3.31	-3.23	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-12.0%	-34,484,000	-30,788,000	-17,412,000	-18,640,000	-21,224,000	-15,230,000	-13,986,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.7%	919	965	671	685	720	754	776	807	558	572	264	275	291	189	199	211	237	148	99.00	106	115
Current Assets	9.7%	707	645	531	545	533	600	649	795	546	559	256	267	283	182	195	207	234	145	96.00	103	112
Cash Equivalents	-60.4%	59.00	149	100	65.00	70.00	57.00	103	370	117	176	88.00	83.00	88.00	45.00	15.00	44.00	61.00	25.00	38.00	37.00	52.00
Net PPE	-2.7%	9.00	10.00	10.00	10.00	8.00	7.00	5.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00
Liabilities	-15.1%	31.00	37.00	35.00	38.00	33.00	33.00	23.00	22.00	16.00	22.00	15.00	18.00	14.00	18.00	17.00	21.00	49.00	56.00	24.00	23.00	22.00
Current Liabilities	-18.5%	22.00	27.00	25.00	28.00	22.00	23.00	16.00	14.00	8.00	14.00	13.00	15.00	11.00	15.00	17.00	21.00	49.00	43.00	12.00	9.00	6.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.00	12.00	13.00	15.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.00	5.00	4.00	2.00	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11.00	12.00	13.00	15.00
Shareholder's Equity	-4.3%	888	928	637	646	687	721	753	786	542	550	249	257	276	171	182	189	188	92.00	75.00	83.00	92.00
Retained Earnings	-7.2%	-713	-665	-620	-571	-524	-482	-445	-408	-377	-357	-331	-316	-294	-278	-266	-257	-257	-249	-238	-229	-219
Additional Paid-In Capital	4.3%	164	157	138	139	140	142	137	133	120	117	70.00	67.00	65.00	45.00	44.00	42.00	41.00	41.00	40.00	39.00	39.00
Shares Outstanding	0.1%	75.00	75.00	65.00	64.00	63.00	63.00	59.00	56.00	55.00	44.00	40.00	39.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,443	-	-	-	1,881	-	-	-	751	-	-	-	383	-	-	-	228	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-21.7%	-43,178	-35,465	-42,230	-33,221	-34,411	-32,732	-30,402	-16,868	-18,428	-20,710	-15,007	-13,077	-20,708	-13,114	-11,154	-10,789	-13,067	19,787	-7,058	-8,747	-8,696
Share Based Compensation	2.4%	9,400	9,182	8,743	8,453	5,994	5,812	5,742	5,208	3,614	2,705	2,643	2,704	1,965	1,610	1,580	1,472	1,015	1,357	612	464	491
Cashflow From Investing	80.7%	-46,202	-239,726	48,032	27,902	46,622	-14,335	-234,097	1,317	-48,888	-215,433	15,575	8,192	-55,104	43,199	-18,032	10,934	-52,925	-60,318	7,740	-6,628	-7,003
Cashflow From Financing	-100.0%	-	324,014	-	-	-	6.00	699	269,890	7,876	323,953	4,758	111	118,721	45.00	-	-16,720	102,470	27,431	18.00	11.00	58.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XENE Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue (note 11)		$ 9,434	$ 18,437
Operating expenses:
Research and development	$ 167,512	105,767	75,463
General and administrative	46,542	32,810	21,967
Total operating expenses	214,054	138,577	97,430
Loss from operations	(214,054)	(129,143)	(78,993)
Other income (expense):
Interest income	27,620	8,713	466
Unrealized fair value gain (loss) on trading securities	3,550	(2,934)	(719)
Foreign exchange gain (loss)	199	(1,891)	358
Other income (expense)	31,369	3,888	105
Loss before income taxes	(182,685)	(125,255)	(78,888)
Income tax recovery (expense) (note 13)	292	(118)	6
Net loss	(182,393)	(125,373)	(78,882)
Net loss attributable to preferred shareholders		(437)	(1,795)
Net loss attributable to common shareholders	(182,393)	(124,936)	(77,087)
Other comprehensive income (loss):
Unrealized gain (loss) on available-for-sale securities (note 6)	2,923	(2,010)
Comprehensive loss	$ (179,470)	$ (127,383)	$ (78,882)
Net loss per common share (note 4):
Basic	$ (2.73)	$ (2.06)	$ (1.77)
Diluted	$ (2.73)	$ (2.06)	$ (1.77)
Weighted-average common shares outstanding (note 4):
Basic	66,889,005	60,542,142	43,627,452
Diluted	66,889,005	60,542,142	43,627,452

XENE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 148,643	$ 57,242
Marketable securities (note 6)	489,439	534,845
Accounts receivable	874	986
Prepaid expenses and other current assets	6,006	7,225
Total current assets	644,962	600,298
Marketable securities, long-term (note 6)	292,792	128,682
Operating lease right-of-use asset, net (note 8)	9,193	10,406
Property, plant and equipment, net (note 7)	9,653	6,500
Deferred tax assets (note 13)	802	509
Prepaid expenses, long-term	7,396	7,751
Total assets	964,798	754,146
Current liabilities:
Accounts payable and accrued expenses (note 9)	25,974	22,214
Operating lease liability (note 8)	1,299	488
Total current liabilities	27,273	22,702
Operating lease liability, long-term (note 8)	9,604	9,947
Total liabilities	36,877	32,649
Shareholders’ equity:
Common shares, without par value; unlimited shares authorized; issued and outstanding: 75,370,977 (December 31, 2022 - 62,587,701) (note 10)	1,436,374	1,065,136
Additional paid-in capital	156,764	142,108
Accumulated deficit	(665,140)	(482,747)
Accumulated other comprehensive loss	(77)	(3,000)
Total shareholders' equity	927,921	721,497
Total liabilities and shareholders’ equity	964,798	754,146
Commitments and contingencies (note 12)

About Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.

CEO	Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA
WEBSITE	xenon-pharma.com
INDUSTRY	Biotechnology
EMPLOYEES	203

Xenon Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Xenon Pharmaceuticals Inc? What does XENE stand for in stocks?

XENE is the stock ticker symbol of Xenon Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Xenon Pharmaceuticals Inc (XENE)?

As of Mon May 13 2024, market cap of Xenon Pharmaceuticals Inc is 3.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XENE stock?

You can check XENE's fair value in chart for subscribers.

What is the fair value of XENE stock?

You can check XENE's fair value in chart for subscribers. The fair value of Xenon Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Xenon Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XENE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Xenon Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether XENE is over valued or under valued. Whether Xenon Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Xenon Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XENE.

What is Xenon Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, XENE's PE ratio (Price to Earnings) is -16.21 and Price to Sales (PS) ratio is 340.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XENE PE ratio will change depending on the future growth rate expectations of investors.